Literature DB >> 11795730

Repeated botulinum toxin A injections in the treatment of spastic equinus foot.

Dimitrios Metaxiotis1, Andrea Siebel, Leonhard Doederlein.   

Abstract

Equinus foot disorder is a common problem for patients with cerebral palsy who are able to ambulate. Botulinum toxin A is a recommended method of treatment for temporary reduction of muscle tone. The efficacy of repeated botulinum toxin A injections in the calf muscles was evaluated in a clinical trial involving 21 children with cerebral palsy and dynamic equinus foot deformity who were able to ambulate. The mean age of the children was 5.7 years. All patients received at least two injections, six patients received at least three injections, and three patients received four injections. The outcome was evaluated using observational and three-dimensional instrumented gait analysis. Significant improvements of the gait parameters were observed at 6 and 18 weeks after the first and second injections. Botulinum toxin A injections in gastrocnemius and soleus muscles may change the natural history of equinus foot deformity in patients with spastic diplegia. Orthopaedic surgery may be postponed or avoided.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11795730     DOI: 10.1097/00003086-200201000-00021

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  9 in total

1.  Costs and consequences of botulinum toxin type A use. Management of children with cerebral palsy in Germany.

Authors:  Francis J Ruiz; Julian F Guest; Almut Lehmann; Alison M Davie; Karen Güttler; Olaf Schlüter; Götz Dreiss
Journal:  Eur J Health Econ       Date:  2004-10

Review 2.  [Botulinum toxin therapy in orthopaedics].

Authors:  L Döderlein
Journal:  Orthopade       Date:  2006-01       Impact factor: 1.087

Review 3.  AbobotulinumtoxinA: A Review in Pediatric Lower Limb Spasticity.

Authors:  Yahiya Y Syed
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

4.  The influence of botulinum toxin A injections into the calf muscles on genu recurvatum in children with cerebral palsy.

Authors:  Matthias C M Klotz; Sebastian I Wolf; Daniel Heitzmann; Simone Gantz; Frank Braatz; Thomas Dreher
Journal:  Clin Orthop Relat Res       Date:  2013-03-06       Impact factor: 4.176

5.  Long-term effect of repeated injections of botulinum toxin in children with cerebral palsy: a prospective study.

Authors:  Aviva Fattal-Valevski; Dafna Domenievitz; Nir Giladi; Shlomo Wientroub; Shlomo Hayek
Journal:  J Child Orthop       Date:  2008-01-23       Impact factor: 1.548

Review 6.  Best clinical practice in botulinum toxin treatment for children with cerebral palsy.

Authors:  Walter Strobl; Tim Theologis; Reinald Brunner; Serdar Kocer; Elke Viehweger; Ignacio Pascual-Pascual; Richard Placzek
Journal:  Toxins (Basel)       Date:  2015-05-11       Impact factor: 4.546

7.  Safety and Efficacy of Repeat Open-Label AbobotulinumtoxinA Treatment in Pediatric Cerebral Palsy.

Authors:  Mauricio R Delgado; Marcin Bonikowski; Jorge Carranza; Edward Dabrowski; Dennis Matthews; Barry Russman; Ann Tilton; Juan Carlos Velez; Anne-Sophie Grandoulier; Philippe Picaut
Journal:  J Child Neurol       Date:  2017-09-15       Impact factor: 1.987

8.  Protocol for The Toxin Study: Understanding clinical and patient reported response of children and young people with cerebral palsy to intramuscular lower limb Botulinum neurotoxin-A injections, exploring all domains of the ICF. A pragmatic longitudinal observational study using a prospective one-group repeated measures design.

Authors:  Lesley R Katchburian; Kate Oulton; Eleanor Main; Christopher Morris; Lucinda J Carr
Journal:  BMJ Open       Date:  2021-04-21       Impact factor: 2.692

Review 9.  Literature Review and Comparison of Two Statistical Methods to Evaluate the Effect of Botulinum Toxin Treatment on Gait in Children with Cerebral Palsy.

Authors:  Angela Nieuwenhuys; Eirini Papageorgiou; Todd Pataky; Tinne De Laet; Guy Molenaers; Kaat Desloovere
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.